Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

By Tran Hai   Zinner Ralph   Blumenschein George   Oh Yun   Papadimitrakopoulou Vassiliki   Kim Edward   Lu Charles   Malik Mubashira   Lum Bert   Herbst Roy  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 499-505

Springer Publishing Company

Access to resources Recommend Favorite

Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer

By Choy Hak   Pyo Hongryull   Kim Jae-sung   MacRae Rob  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 6, 2001-06 ,pp. : 963-974

Informa Healthcare

Access to resources Recommend Favorite

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination

By Esteban-Gonzalez Emilio   Fernández Yolanda   Villanueva Noemí   Fra Joaquin   Muñiz Isabel   Palacio Isabel   Vieitez Jose   Uña Esther   Mareque Beatriz   Lacave Angel  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 597-601

Springer Publishing Company

Access to resources Recommend Favorite

Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

By Schuette W.  

Clinical Drug Investigation, Vol. 21, Iss. 3, 2001-03 ,pp. : 161-168

Adis International

Access to resources Recommend Favorite